European Biotech Acquisition Corp. Warrant
EBACW
EBACW was delisted on the 2nd of March, 2023.
32 hedge funds and large institutions have $2.73M invested in European Biotech Acquisition Corp. Warrant in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
193% more capital invested
Capital invested by funds: $932K → $2.73M (+$1.8M)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
7% more funds holding
Funds holding: 30 → 32 (+2)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$31.8K |
| 2 |
CCM
CAAS Capital Management
New York
|
+$5.64K |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$5K |
| 4 |
AGC
Angelo Gordon & Co
New York
|
+$2.26K |
| 5 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$510 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$61K |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$20K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$68 |
| 4 |
FTCM
Fir Tree Capital Management
New York
|
-$62 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OAC
26
OMERS Administration Corp
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
VI
27
Vestcor Inc
Fredericton,
New Brunswick, Canada
| $1K | – | – | – |
|
|
OMC
28
Old Mission Capital
Chicago,
Illinois
| $1K | +$510 | +3,014 | +26% |
|
|
MF
29
Magnetar Financial
Evanston,
Illinois
| $3 | +$5K | +29,532 | New |
|
|
30
Citadel Advisors
Miami,
Florida
| – | -$61K | -303,681 | Closed |
|
|
SCM
31
Suvretta Capital Management
New York
| – | -$20K | -100,000 | Closed |
|
|
SCC
32
Spring Creek Capital
Wichita,
Kansas
| – | -$3K | -16,666 | Closed |
|
|
33
UBS Group
Zurich,
Switzerland
| – | -$68 | -400 | -29% |
|
EBACW Hedge Fund Activity: Q2 2022 in Review
32 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Warrant (EBACW) for Q2 2022, worth a combined $2.73M — up 193% from $932K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EBACW positions and 3 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Mangrove Partners, opening a new position worth an estimated $31.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $61K sold.
- 32 institutional investors held European Biotech Acquisition Corp. Warrant (EBACW) as of Q2 2022, up from 30 in Q1 2022.
- Funds reported $2.73M of European Biotech Acquisition Corp. Warrant stock for Q2 2022, up 193% quarter-over-quarter.
- 5 funds opened new European Biotech Acquisition Corp. Warrant positions in Q2 2022 and 3 closed out, a net change of +2 holders.
- The largest European Biotech Acquisition Corp. Warrant buyer in Q2 2022 was Mangrove Partners, an estimated $31.8K added.
- The largest European Biotech Acquisition Corp. Warrant seller in Q2 2022 was Citadel Advisors, an estimated $61K sold.
Based on aggregated 13F filings for Q2 2022.